Biotalys NV (BTLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotalys NV (BTLS) has a cash flow conversion efficiency ratio of -0.154x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.05 Million ≈ $-3.56 Million USD) by net assets (€19.81 Million ≈ $23.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BTLS equity to assets ratio to measure how much of total assets are equity-financed.
Biotalys NV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biotalys NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Biotalys NV cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Biotalys NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotalys NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chung Fu Tex-International Corp
TW:1435
|
-0.010x |
|
Arrow Exploration Corp
V:AXL
|
0.032x |
|
Sedana Medical AB
ST:SEDANA
|
-0.006x |
|
SSH Communications Security Oyj
HE:SSH1V
|
0.070x |
|
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
|
-2.256x |
|
Amulaire Thermal Technology
TW:2241
|
0.007x |
|
iFabric Corp
TO:IFA
|
-0.083x |
|
DAE HWA Pharmaceutical Co. Ltd
KQ:067080
|
0.004x |
Annual Cash Flow Conversion Efficiency for Biotalys NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biotalys NV from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Biotalys NV (BTLS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €27.61 Million ≈ $32.27 Million |
€-12.65 Million ≈ $-14.79 Million |
-0.458x | +35.91% |
| 2023-12-31 | €25.57 Million ≈ $29.89 Million |
€-18.28 Million ≈ $-21.37 Million |
-0.715x | -35.65% |
| 2022-12-31 | €38.11 Million ≈ $44.56 Million |
€-20.09 Million ≈ $-23.49 Million |
-0.527x | -85.36% |
| 2021-12-31 | €58.91 Million ≈ $68.88 Million |
€-16.75 Million ≈ $-19.59 Million |
-0.284x | +23.49% |
| 2020-12-31 | €25.65 Million ≈ $29.99 Million |
€-9.53 Million ≈ $-11.15 Million |
-0.372x | +4.76% |
| 2019-12-31 | €21.07 Million ≈ $24.64 Million |
€-8.22 Million ≈ $-9.61 Million |
-0.390x | -- |
About Biotalys NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6… Read more